Head-to-Head lupus drug study aims to find better treatment

NCT ID NCT07069972

Summary

This study will compare two existing medications for systemic lupus erythematosus (SLE) to see which works better and is safer. Researchers will observe 180 adults with moderate-to-severe lupus who choose either telitacicept or belimumab alongside their current treatments. The study will track how well each drug controls lupus symptoms and improves kidney function in patients with lupus nephritis.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Qianfoshan Hospital

    Jinan, Shandong, 250000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.